Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow TherapeuticsMD, Inc.

Get SEC filing alerts via email and in your feed for TherapeuticsMD, Inc.

TXMD

TherapeuticsMD, Inc.

About TherapeuticsMD, Inc.

TherapeuticsMD is a pharmaceutical royalty company specializing in women’s health products. It owns or licenses rights to products like IMVEXXY, BIJUVA, and ANNOVERA, generating revenue through royalties from licensed pharmaceutical products sold worldwide. The company focuses on licensing, patent protection, and strategic partnerships, relying on third-party manufacturers and licensees to commercialize its portfolio in various global markets.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from TherapeuticsMD, Inc.

1
1
TherapeuticsMD, Inc. TherapeuticsMD Reports Net Income of $95,000 in Q1 2026, Revenue Up 84%

Via official filing (AI summary) | 23 days ago | 0 comments

2
1
TherapeuticsMD, Inc. TherapeuticsMD Reports Improved Net Loss of $569,000 for Fiscal Year 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
TherapeuticsMD, Inc. TherapeuticsMD Reports Net Income of $152,000 for Q3 2025, Significant Year-Over-Year Improvement

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
TherapeuticsMD, Inc. TherapeuticsMD Reports Revenue Growth and Improved Losses in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
TherapeuticsMD, Inc. TherapeuticsMD Reports 25.6% Revenue Growth and $653,000 Net Loss in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
TherapeuticsMD, Inc. TherapeuticsMD Reports Improved Net Loss and Increased License Revenue for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
TherapeuticsMD, Inc. TherapeuticsMD Reports Improved Financials, Reduced Losses Following Business Model Shift to Pharmaceutical Royalty Company

Via official filing (AI summary) | over 1 year ago | 0 comments